Pharmacogenomics of Cardiovascular Drugs

Linnea M. Baudhuin

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Pharmacologic therapies are essential in the management of patients with cardiovascular and thrombotic disorders because they are able to modify components of the pathways involved in these disorders. Nevertheless, responses to different drugs vary significantly, and the best clinical outcome frequently involves a delicate balance between risk and benefit. The field of pharmacogenomics has led to the emergence of individualized medicine that has revolutionized modern medical practice, allowing for a deeper understanding of pathophysiology, increased diagnostic specificity and better markers for risk stratification, as well as an enhanced potential for gene therapy. Management of drugs prescribed to treat cardiovascular abnormalities have been shown to benefit from pharmacogenetics, and our focus in this review will be on the pharmacogenetics related to some of the more common drugs that fall into this category.

Original languageEnglish (US)
Title of host publicationPharmacogenomics in Clinical Therapeutics
PublisherJohn Wiley and Sons
Pages98-126
Number of pages29
ISBN (Print)9780470657348
DOIs
StatePublished - Feb 24 2012

Fingerprint

Cardiovascular Agents
Pharmacogenetics
Pharmaceutical Preparations
Cardiovascular Abnormalities
Precision Medicine
Genetic Therapy
Therapeutics

Keywords

  • Anticoagulant
  • Antiplatelet
  • Aspirin
  • Cardiovascular
  • Clopidogrel
  • pharmacogenetics
  • Statin

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Baudhuin, L. M. (2012). Pharmacogenomics of Cardiovascular Drugs. In Pharmacogenomics in Clinical Therapeutics (pp. 98-126). John Wiley and Sons. https://doi.org/10.1002/9781119959601.ch7

Pharmacogenomics of Cardiovascular Drugs. / Baudhuin, Linnea M.

Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, 2012. p. 98-126.

Research output: Chapter in Book/Report/Conference proceedingChapter

Baudhuin, LM 2012, Pharmacogenomics of Cardiovascular Drugs. in Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, pp. 98-126. https://doi.org/10.1002/9781119959601.ch7
Baudhuin LM. Pharmacogenomics of Cardiovascular Drugs. In Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons. 2012. p. 98-126 https://doi.org/10.1002/9781119959601.ch7
Baudhuin, Linnea M. / Pharmacogenomics of Cardiovascular Drugs. Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, 2012. pp. 98-126
@inbook{e4dbc300a13f41a98775fa879ce3dab4,
title = "Pharmacogenomics of Cardiovascular Drugs",
abstract = "Pharmacologic therapies are essential in the management of patients with cardiovascular and thrombotic disorders because they are able to modify components of the pathways involved in these disorders. Nevertheless, responses to different drugs vary significantly, and the best clinical outcome frequently involves a delicate balance between risk and benefit. The field of pharmacogenomics has led to the emergence of individualized medicine that has revolutionized modern medical practice, allowing for a deeper understanding of pathophysiology, increased diagnostic specificity and better markers for risk stratification, as well as an enhanced potential for gene therapy. Management of drugs prescribed to treat cardiovascular abnormalities have been shown to benefit from pharmacogenetics, and our focus in this review will be on the pharmacogenetics related to some of the more common drugs that fall into this category.",
keywords = "Anticoagulant, Antiplatelet, Aspirin, Cardiovascular, Clopidogrel, pharmacogenetics, Statin",
author = "Baudhuin, {Linnea M.}",
year = "2012",
month = "2",
day = "24",
doi = "10.1002/9781119959601.ch7",
language = "English (US)",
isbn = "9780470657348",
pages = "98--126",
booktitle = "Pharmacogenomics in Clinical Therapeutics",
publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Pharmacogenomics of Cardiovascular Drugs

AU - Baudhuin, Linnea M.

PY - 2012/2/24

Y1 - 2012/2/24

N2 - Pharmacologic therapies are essential in the management of patients with cardiovascular and thrombotic disorders because they are able to modify components of the pathways involved in these disorders. Nevertheless, responses to different drugs vary significantly, and the best clinical outcome frequently involves a delicate balance between risk and benefit. The field of pharmacogenomics has led to the emergence of individualized medicine that has revolutionized modern medical practice, allowing for a deeper understanding of pathophysiology, increased diagnostic specificity and better markers for risk stratification, as well as an enhanced potential for gene therapy. Management of drugs prescribed to treat cardiovascular abnormalities have been shown to benefit from pharmacogenetics, and our focus in this review will be on the pharmacogenetics related to some of the more common drugs that fall into this category.

AB - Pharmacologic therapies are essential in the management of patients with cardiovascular and thrombotic disorders because they are able to modify components of the pathways involved in these disorders. Nevertheless, responses to different drugs vary significantly, and the best clinical outcome frequently involves a delicate balance between risk and benefit. The field of pharmacogenomics has led to the emergence of individualized medicine that has revolutionized modern medical practice, allowing for a deeper understanding of pathophysiology, increased diagnostic specificity and better markers for risk stratification, as well as an enhanced potential for gene therapy. Management of drugs prescribed to treat cardiovascular abnormalities have been shown to benefit from pharmacogenetics, and our focus in this review will be on the pharmacogenetics related to some of the more common drugs that fall into this category.

KW - Anticoagulant

KW - Antiplatelet

KW - Aspirin

KW - Cardiovascular

KW - Clopidogrel

KW - pharmacogenetics

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84887196938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887196938&partnerID=8YFLogxK

U2 - 10.1002/9781119959601.ch7

DO - 10.1002/9781119959601.ch7

M3 - Chapter

AN - SCOPUS:84887196938

SN - 9780470657348

SP - 98

EP - 126

BT - Pharmacogenomics in Clinical Therapeutics

PB - John Wiley and Sons

ER -